Navigation Links
Lymphoma's Link to Hepatitis C

Researchers at the University of Hopkins found a new study shows some cancer patients who also have the hepatitis C virus may benefit from treatment with the drug, interferon. Past research has suggested a connection between the hepatitis C virus and some B-cell non-Hodgkin's lymphoma's. //A patient with both of these diseases was treated with the antiviral treatment interferon. The patient responded causing researchers in Paris to study whether the treatment could help other patients with a similar diagnosis.

Nine patients who had splenic lymphoma with villous lymphocytes, a specific type of B-cell non-Hodgkin's lymphoma, and the hepatitis C virus infection were treated with interferon either alone or in combination with the drug, ribavirin. Outcomes of these patients were then compared to six similarly treated patients with splenic lymphoma with villous lymphocytes who did not have the hepatitis C virus infection.

Researchers report seven of the patients treated with interferon had a complete remission of their cancer. The other two patients had a partial and complete remission after the addition of ribavirin was added to their treatment. In contrast, none of the six patients without the hepatitis C virus responded to the interferon therapy.

Researchers felt that in patients with splenic lymphoma with villous lymphocytes who are infected with the hepatitis C virus, treatment with interferon can lead to remission of the lymphoma.


'"/>




Page: 1

Related medicine news :

1. Vitamin B for Hepatitis
2. Hepatitis G May Boost HIV Survival
3. Cure for Hepatitis B
4. Hepatitis E virus made impotent
5. Sharing injection equipment spreads Hepatitis C
6. Hepatitis shots is promising
7. Need for Hepatitis Booster Questioned
8. Good News for HIV Patients Also Suffering From Hepatitis C Virus
9. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
10. The Effectiveness Of Hepatitis B Vaccine Questioned
11. New Treatment for Chronic Hepatitis B
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic ... manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: